Brielle Benyon | Authors


Survival in Advanced ESCC Improved With Frontline Nivolumab Plus Ipilimumab or Chemotherapy

July 22, 2021

Improved survival outcomes were reported with the addition of nivolumab to either ipilimumab or chemo-therapy vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or metastatic esophageal squamous cell carcinoma.